AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00901511 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Baseline WLL
Description: Scheduled bilateral WLL
Study NCT00901511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline WLL
Description: Scheduled bilateral WLL
Study NCT00901511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Inhaled GM-CSF
Study NCT00901511 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rescue WLL
Description: Unscheduled bilateral WLL
Study NCT00901511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue WLL
Description: Unscheduled bilateral WLL
Study NCT02847858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents
Description: School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
Study NCT04442321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PENS plus exercise
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week.
Study NCT04442321 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham PENS plus exercise
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week.
Study NCT03074266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GEM Hemochron 100 ACT
Description: Activated Clotting Time
Study NCT04415879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N-95 Respirator
Description: N-95 mask will be worn as personal protective equipment during a graded exercise test
Study NCT04415879 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N-95 Respirator
Description: N-95 mask will be worn as personal protective equipment during a graded exercise test
Study NCT04415879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloth Face Mask
Description: A cloth mask will be worn as personal protective equipment during a graded exercise test
Study NCT04415879 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cloth Face Mask
Description: A cloth mask will be worn as personal protective equipment during a graded exercise test
Study NCT04415879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Graded exercise test
Description: No personal protective equipment during a graded exercise test
Study NCT04622839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tylenol and NSAIDS (Ibuprofen, diclofenac)
Description: This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~* Agents used in nerve block (lidocaine vs ropivacaine)~* Location of injection for analgesic~* Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~* Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~* Number of pills in the initial opioid prescription~* Instructions for sling wear (duration of use or type of sling)~* Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage.
Study NCT04415879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Graded exercise test
Description: No personal protective equipment during a graded exercise test
Study NCT02798991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3179106
Description: It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
Study NCT02798991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
Study NCT02877082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Given IV
Study NCT02877082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT02877082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT03931421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T treatment
Description: a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.
Study NCT01466348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol and Caffeine
Description: Paracetamol 1000 mg and caffeine 130 mg
Study NCT01466348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 1000 mg
Study NCT00810901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organ Donor
Description: Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
Study NCT03704272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SunBrite
Description: SunBrite is a family-empowered injury risk mitigation intervention with 3 core components: screening for the risk of supervisory neglect associated with traumatic injury in very young children; a brief behavioral intervention using motivational interviewing designed to provide feedback to the caregiver on supervisory risk and traumatic injury; and a referral to treatment for ongoing risks such as substance abuse, trauma or mental illness, requiring specific clinical interventions.
Study NCT03970733 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA15
Description: a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
Study NCT03970733 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBS (Phosphate Buffered Saline)
Study NCT06541015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENSity 10 TENS Stimulator
Description: InTENSity 10 TENS stimulator is a portable electrotherapy device featuring Transcutaneous Electrical Nerve Stimulation (TENS) therapeutic device. The stimulator sends a gentle electrical current to underlying nerves and muscle group via electrodes applied on the skin. The parameters of device are controlled by the buttons.
Study NCT01578395 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiation exposure
Description: what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
Study NCT01578395 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose radiation exposure
Description: what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
Study NCT01578395 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose radiation exposure
Description: what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
Study NCT01578395 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: High-dose radiation exposure
Description: what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
Study NCT01578395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No radiation exposure
Description: Subjects not undergoing any radiation exposure
Study NCT01578395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No radiation exposure
Description: Subjects not undergoing any radiation exposure
Study NCT02729974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: rapid testing of blood clot formation
Study NCT02729974 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
Study NCT04102215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEARO
Description: Robotic system for otological procedures
Study NCT04102215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTOPLAN
Description: Otological surgical planning software
Study NCT03130166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Description: Use of intracorporeal anastomosis technique
Study NCT03130166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: Use of the conventional extracorporeal anastomosis technique
Study NCT01059474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal DMPS
Description: 12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS.
Study NCT03816085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoes
Description: Shoes with different heel heights
Study NCT00303498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitexsentin sodium
Description: sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
Study NCT00303498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo identical to the study drug in description, dose and duration
Study NCT01741922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA evening
Description: Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
Study NCT01741922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic morning
Description: Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
Study NCT01741922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos morning
Description: Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
Study NCT01741922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo evening
Description: Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
Study NCT00810901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Prevention
Description: Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
Study NCT04139954 — intervention group
Intervention type: OTHER
Intervention: There is no intervention in the study
Description: There is no intervention in the study
Study NCT01988103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 20 mg tablet BID for 68 weeks
Study NCT01988103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet BID for 16 weeks
Study NCT01988103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet BID for 16 weeks
Study NCT03933787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg
Description: Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
Study NCT03933787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
Study NCT05606185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retraction method
Description: Three dimensional evaluation of root resorption using cone beam computed tomography
Study NCT05606185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retraction method
Description: Three dimensional evaluation of root resorption using cone beam computed tomography
Study NCT02133625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT02133625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Study NCT03906656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Brace
Description: The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
Study NCT03906656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KAFO/SCO
Description: Current knee ankle foot orthosis that the subject was wearing at baseline
Study NCT03776604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy.
Study NCT01163981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of ultrasound guidance in cannulation
Description: Use of guidance with duplex ultrasound to complete cannulation of dialysis access
Study NCT03324724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative cognitive-affective therapy for adolescents (ICAT-A)
Description: Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
Study NCT04516629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: heart rate variability, pulse diagnosis device
Description: check heart rate and pulse rate
Study NCT01729481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m² iv weekly
Study NCT03929471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Target weight correction protocol
Description: The intervention group will undergo target weight correction process based on time averaged fluid overload measurement (by bio-impedance).
Study NCT01523392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Min - 90mg/Max - 180mg tablets (loading dose)
Study NCT01523392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg (once daily)/Max - 600mg tablets (loading dose)
Study NCT01729481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100mg, once per day
Study NCT01729481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m², q2weeks
Study NCT01729481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: 400 mg/m², q2weeks
Study NCT01729481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m², q2weeks
Study NCT01729481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
Study NCT03933787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ergometric test in healthy volunteers
Description: The volunteers will undergo an ergometric test in each session
Study NCT03933787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ergometric test in healthy volunteers
Description: The volunteers will undergo an ergometric test in each session
Study NCT02638740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCALING AND ROOT PLANING (SRP)
Description: Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
Study NCT02638740 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCALING AND ROOT PLANING (SRP)
Description: Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
Study NCT02638740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MUSTARD OIL AND SALT MASSAGE WITH SRP
Description: Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
Study NCT02409251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and feedback